Loading quotes...
Forecast
The analysts' average price target is €74.57 (+9.04%). The median is €77.67 (+13.57%).
| Buy |
11 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
Kiniksa Pharmaceuticals International names Ross Moat COO and Eben Tessari chief strategy officer
Kiniksa Pharmaceuticals International’s board has appointed Ross Moat as chief operating officer effective Friday; Moat will also remain responsible for commercial activities. Eben Tessari was named chief strategy officer and will continue to lead strategy, business development and technical operations as well as the company’s AI initiatives. Both appointments involve no changes to compensation arrangements; Kiniksa is headquartered in London and trades on Nasdaq under the ticker KNSA. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 213.44M | 60.45% |
| Gross profit | 115.62M | 58.90% |
| Net profit | 22.28M | 47.29% |
| EBITDA | 24.24M | 22.97% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €5.21B |
Number of shares | 76.21M |
52-week high/low | €71.58 - €28.87 |
| Dividends | No |
Beta | 0.09 |
P/E ratio | 74.09 |
PEG ratio | 0.04 |
P/B ratio | 9.40 |
P/S ratio | 7.19 |
Company profile
| Name | Kiniksa Pharmaceuticals International PLC Class A |
| CEO | Sanj K. Patel |
| Headquarters | London,
gl United Kingdom |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| Employees | 366 |
Discover assets
Shareholders of Kiniksa Pharmaceuticals International PLC Class A also invest in the following assets
